| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 06/16/2005 | WO2005053705A1 Use of a cyclopentenone prostaglandin for delaying the onset and/or preventing the continuation of labour |
| 06/16/2005 | WO2005053703A1 Combination therapy for dementia, depression and apathy |
| 06/16/2005 | WO2005053696A1 Treatment of spondylarthropathies |
| 06/16/2005 | WO2005053683A1 A method of preventing or treating glaucoma |
| 06/16/2005 | WO2005053674A1 Complexes of cyclic polyaza chelators with cations of alkaline earth metals for enhanced biological activity |
| 06/16/2005 | WO2005053665A1 Treating infectious diseases using ice inhibitors |
| 06/16/2005 | WO2005053661A2 Pharmaceutical combinations |
| 06/16/2005 | WO2005053613A2 Combinations for the treatment of fungal infections |
| 06/16/2005 | WO2005053605A2 Therapeutic liposomes |
| 06/16/2005 | WO2005053387A1 Non-human mammalian and non-mammalian animal models of age-related memory impairment |
| 06/16/2005 | WO2005039528A3 Composition for the treatment of arthrosis/arthritis, especially for treating joints |
| 06/16/2005 | WO2005037928A3 Compounds for dual photodiagnosis and therapy |
| 06/16/2005 | WO2005034883A3 A method of healing skin wounds in mammals and a composition therefor |
| 06/16/2005 | WO2005032589A8 Prevention and treatment for gvhd |
| 06/16/2005 | WO2005023305A3 Modulating cell activity by using an agent that reduces the level of cholesterol within a cell |
| 06/16/2005 | WO2005020962A8 Self-nanoemulsifying oily formulation for the administration of poorly water-soluble drugs |
| 06/16/2005 | WO2005018650A3 Anti-bacterial composition, especially for controlling gram-negative bacteria, comprising a peptide and an advantageously hydrophobic anti-bacterial agent |
| 06/16/2005 | WO2004093881A3 Use of dipyridamole or mopidamole for treatment and prevention of thrombo-embolic diseases and disorders caused by excessive formation of thrombin and/or by elevated expression of thrombin receptors |
| 06/16/2005 | WO2004084825A3 Wound healing composition derived from low platelet concentration plasma |
| 06/16/2005 | WO2004067028A8 Compound for attenuating reaction of recipient tissues to an exogenic material and method for preparing an implant/transplant for contacting tissues of the organism of said recipient |
| 06/16/2005 | WO2004056750A8 Cyclopentil-substituted glutaramide compounds as endopeptidase inhibitors |
| 06/16/2005 | WO2004050013A3 Material compositions and related systems and methods for treating cardiac conditions |
| 06/16/2005 | WO2003012072A3 Monoclonal antibodies to activated erbb family members and methods of use thereof |
| 06/16/2005 | WO1991001624A8 Use of calcium antagonists for treating scars |
| 06/16/2005 | US20050132430 Igamete recruitment and developmental competence in mammals by inhibiting the de-nova sterol biosynthesis and/or promoting sterol efflux |
| 06/16/2005 | US20050132428 Cyclic amp phosphodiesterase 4d7 isoforms and methods of use |
| 06/16/2005 | US20050131064 Administering powder or aerosol to nasal mucous membrane |
| 06/16/2005 | US20050131063 Methods and composition based on discovery of metabolism of nitroglycerin |
| 06/16/2005 | US20050131060 Spirolaxine acts as active principle for treatment of those pathologies responding to activation of PPAR gamma receptor, such as acute malignant haemopathies. and Type 2 insulin-resistant diabetes |
| 06/16/2005 | US20050131059 Anti-cancer combinations |
| 06/16/2005 | US20050131046 Administering to a human a therapeutically effective amount of descarboethoxyloratadine |
| 06/16/2005 | US20050131042 HIV protease inhibiting compounds |
| 06/16/2005 | US20050131035 Medicaments |
| 06/16/2005 | US20050131026 Bronchitis; chronic obstructive pulmonary disease; antihistamines; pneumonia |
| 06/16/2005 | US20050131023 Use of pleuromutilins for the treatment of disorders caused by helicobacter pylori |
| 06/16/2005 | US20050131021 Phenoxy piperidines for treating diseases such as schizophrenia and depression |
| 06/16/2005 | US20050130990 especially dimethylphenylpiperazinium; treating a variety of pulmonary diseases with fewer side effects than other anti-inflammatory drugs, such as steroids |
| 06/16/2005 | US20050130987 Methods of treating vasomotor symptoms |
| 06/16/2005 | US20050130986 Treatment of spondylarthropathies |
| 06/16/2005 | US20050130979 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline (NBQX) or the quinoxalinedione is 9-methyl-amino-6-nitro-hexahydro-benzo(F) quinoxalinedione (PNQX) for treating demyelinating disorders |
| 06/16/2005 | US20050130965 Inhibitors of p38 kinase |
| 06/16/2005 | US20050130945 Preventing recurrence of breast cancer with atamestane and toremifene |
| 06/16/2005 | US20050130941 Methods of treating alzheimer's disease |
| 06/16/2005 | US20050130935 Combination of a beta-2-adrenoceptor agonists and an aminosugars and their use for the treatment immunomodulatory disorders |
| 06/16/2005 | US20050130929 For introduction of a disc prosthesis or implant; involves providing substance(s) beneficial to the intervertebral disc through a cannulated element |
| 06/16/2005 | US20050130900 Sustained release drug formulations containing a carrier peptide |
| 06/16/2005 | US20050130891 Containing at least two of the following active substances A, B, C, wherein: A=at least one hormone stimulating the production of cAMP; B=at least one substance inhibiting the degradation of a cyclic nucleotide; C=at least one hormone stimulating the production of cGMP |
| 06/16/2005 | US20050130882 Combination therapy including 9-nitro-20(S)-camptothecin |
| 06/16/2005 | US20050130876 Use of substances for treating tumors |
| 06/16/2005 | US20050130242 Uses of aldose-1-epimerase (mutarotase) for diagnosis and therapy of inflammatory diseases and sepsis |
| 06/16/2005 | US20050130218 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof |
| 06/16/2005 | US20050130146 Histone deactylase for use in identifying modulators for prevention and treatment of cell proliferative disorders |
| 06/16/2005 | US20050130145 polynucleotides which identify and encode human secreted proteins (SECP); expression vectors, host cells, antibodies, and agonists; drug screening |
| 06/16/2005 | US20050129791 Curcuminoid compositions exhibiting synergistic inhibition of the expression and/or activity of cyclooxygenase-2 |
| 06/16/2005 | US20050129781 Colonic purgative composition with soluble binding agent |
| 06/16/2005 | US20050129780 Relief of aids symptoms |
| 06/16/2005 | US20050129742 Antimicrobial article with diffusion control layer |
| 06/16/2005 | US20050129736 Compositions and methods for treating or preventing diseases of body passageways |
| 06/16/2005 | US20050129730 Tissue composites and uses thereof |
| 06/16/2005 | US20050129723 Skin care composition that mediates cell to cell communication |
| 06/16/2005 | US20050129714 Vaccine against salmonid rickettsial septicaemia based on arthrobacter cells |
| 06/16/2005 | US20050129699 Tumor necrosis factor (TNF)-related apoptosis-inducing ligands; anticarcinogenic and antiproliferative agents; graft versus host disease, AIDS, neurodegenerative disorders |
| 06/16/2005 | US20050129694 At least one (SEK) kinase inhibitor that acts in an synergistic manner to those inhibiting the virus multiplication for the Raf/MEK/ERK signal transmission path; influenza viricides |
| 06/16/2005 | US20050129667 treating leukemia or bone cancer by injecting a samarium comples of ethylenediaminetetramethanephosphonic acid and another chemotherapeutic agent; stem cell/bone marrow transplantation and/or restoration; patient is not subjected to total body irradiation |
| 06/16/2005 | US20050129663 Cellular therapy; for promoting axonal regeneration in the CNS, wound healing and treatment of myocardial infarction and spinal cord injury |
| 06/16/2005 | US20050129659 Synergistically effective combinations of dihaloacetamide compounds and interferon or ribavirin against HCV infections |
| 06/16/2005 | US20050129657 Interferon-alpha induced gene |
| 06/16/2005 | US20050129621 Aerosol formulations for pulmonary administration of medicaments to produce a systemic effect |
| 06/16/2005 | US20050129616 Antibodies that immunospecifically bind to TRAIL receptors |
| 06/16/2005 | DE60103627T2 SELBSTEMULGIERENDES ARZNEISTOFFVERABREICHUNGSSYSTEM, wobei das Fettmittel optional ist A self-DRUG ADMINISTRATION SYSTEM, wherein the fat means is optional |
| 06/16/2005 | DE10352449A1 Product for preventing or treating Alzheimer's disease comprises sphingomyelin and/or an activator of endogenous sphingomyelin synthesis and/or an inhibitor of endogenous sphingomyelin degradation |
| 06/16/2005 | DE10352137A1 Verwendung sulfatierter Hyaluronsäure Use of sulfated hyaluronic acid |
| 06/16/2005 | DE10349979A1 Medikamentöse gezielte lokale Lipolyse Drug targeted local lipolysis |
| 06/16/2005 | DE10349722A1 Zusammensetzung zur Arthrose-/Arthritisbehandlung, insbesondere von Gelenken Composition for arthrosis / arthritis treatment, especially of joints |
| 06/16/2005 | CA2589908A1 Use of a cyclopentenone prostaglandin for delaying for the onset and/or preventing the continuation of labour |
| 06/16/2005 | CA2589528A1 Use of a cyclopentenone prostaglandin for delaying the onset and/or preventing the continuation of labour |
| 06/16/2005 | CA2548456A1 Combination therapy |
| 06/16/2005 | CA2548454A1 Medicament comprising recombinant antibody against chemokine receptor ccr4 |
| 06/16/2005 | CA2548135A1 Synthetic hla binding peptide analogues and uses thereof |
| 06/16/2005 | CA2547791A1 Therapeutics use of pyridinium compounds to modulate naadp activity |
| 06/16/2005 | CA2547670A1 Treating infectious diseases using ice inhibitors |
| 06/16/2005 | CA2547668A1 A biomimetic composition reinforced by a polyelectrolytic complex of hyaluronic acid and chitosan |
| 06/16/2005 | CA2546926A1 Compositions for the treatment of afflictions of the oral cavity and upper respiratory tract |
| 06/16/2005 | CA2546738A1 Pharmaceutical combinations |
| 06/16/2005 | CA2546710A1 Local intraosseous administration of bone forming agents and anti-resorptive agents, and devices therefor |
| 06/16/2005 | CA2546649A1 Treatment of rheumatoid arthritis with hypoxia-inducible factor 1.alpha. antagonists |
| 06/16/2005 | CA2536393A1 Use of liposomes which are small unilamellar vesicles for the removal of an entity from a biological sample |
| 06/15/2005 | EP1541684A1 Smg-1-binding protein and method of screening substance controlling its activity |
| 06/15/2005 | EP1541554A1 Crystal for oral solid drug and oral solid drug for dysuria treatment containing the same |
| 06/15/2005 | EP1541197A1 Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists |
| 06/15/2005 | EP1541175A2 Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions |
| 06/15/2005 | EP1541171A1 Therapeutics for diabetes mellitus |
| 06/15/2005 | EP1541161A1 Tablet composition containing chinese orthodox medicine extract and process for producing the same |
| 06/15/2005 | EP1541151A1 REMEDY FOR GLAUCOMA COMPRISING Rho KINASE INHIBITOR AND PROSTAGLANDINS |
| 06/15/2005 | EP1541125A1 Spreadable compositions for topical use, a process of making same and uses thereof |
| 06/15/2005 | EP1541041A1 Pharmaceutical and/or dietary compositions against stress |
| 06/15/2005 | EP1541036A1 Algae feeds for aquaculture and agriculture |
| 06/15/2005 | EP1540627A2 Immunotherapeutic compositions and methods for the treatment of moderately to well-differentiated cancers |
| 06/15/2005 | EP1540332A1 Methods of screening compounds for grk6 modulating activity |
| 06/15/2005 | EP1539990A2 PSMCs AS MODIFIERS OF THE RB PATHWAY AND METHODS OF USE |